Hepatect Cp (Human Hepatitis B Immunoglobulin)

Hepatect Cp is used to provide passive immunity against hepatitis B virus in specific clinical situations.

• Post‑exposure prophylaxis for individuals who have been exposed to hepatitis B through needlestick injuries, sexual contact, or perinatal transmission.
• Prevention of hepatitis B infection in newborns of hepatitis B‑positive mothers when active vaccination is delayed or contraindicated.
• Prophylaxis in patients undergoing hemodialysis who are at high risk for hepatitis B exposure.
• Prevention of hepatitis B recurrence after orthotopic liver transplantation in recipients receiving a hepatitis B‑positive graft.
• Supplementation of hepatitis B vaccine in immunocompromised patients with inadequate serologic response.

The safety profile of Hepatect Cp reflects the typical reactions observed with human immunoglobulin products administered intravenously.

Common

• Mild fever or chills during or shortly after infusion.
• Headache or fatigue.
• Localized pain, erythema, or swelling at the injection site.
• Nausea or mild gastrointestinal discomfort.

Serious

• Acute allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Severe hypotension or cardiovascular collapse.
• Hemolysis or renal impairment related to immune complex formation.
• Transfusion‑related acute lung injury (TRALI).

Before prescribing Hepatect Cp, clinicians should evaluate several precautionary factors to minimize risk and ensure appropriate use.

• Assess patient history for hypersensitivity to human immunoglobulins or blood‑derived products.
• Verify hepatitis B surface antigen status and anti‑HBs antibody levels to determine need for passive immunization.
• Monitor vital signs and observe for infusion‑related reactions during the first administration.
• Adjust infusion rate in patients with cardiovascular disease or compromised circulatory status.
• Use caution in pregnant or breastfeeding women, as safety data are limited.
• Ensure proper aseptic technique to prevent contamination of the injectable solution.

Hepatect Cp may interact with other agents that affect immune function or infusion safety.

Avoid

• Concurrent administration of other blood‑derived products (e.g., plasma, albumin) without appropriate spacing, which can increase the risk of immune complex formation.
• Live vaccines administered within 4 weeks of Hepatect Cp, as passive antibodies may interfere with vaccine efficacy.

Use with caution

• Immunosuppressive drugs (e.g., corticosteroids, calcineurin inhibitors) that may alter the patient’s response to passive antibodies.
• Anticoagulants or antiplatelet agents, because infusion reactions can occasionally trigger bleeding or thrombocytopenia.
• Renal‑impairing medications, as immune complexes may affect kidney function in susceptible individuals.